A Phase 3 interventional study of Aripiprazole and Escitalopram in Major Depressive Disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2021-12-22.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing aripiprazole in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Aripiprazole · Depressive Disorder, Major.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, this one is the 17th largest by enrollment, is one of 4 that started in 2010, is one of 13 in phase 3, and was the 16th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 33 studies testing aripiprazole in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:
Peking University · Sites in China
Ages 18–55
Xinyu Zhou · Sites in China
Ages 12–17
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 66 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 173 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 173 across the 33 interventional studies. Of the 26 that completed or were terminated, 17 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 25th largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2010, is one of 23 in phase 3, and was the 12th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
1 of the studies testing aripiprazole in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011693Xinyu ZhouSwitching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing aripiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD). Enrollment into the study will be from eligible participants who have completed participation in Protocol 31-08-255 [NCT01111539], 31-08-256 [NCT01111552], or 31-08-263 [NCT01111565] ("rollover" participants).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the maximum tolerated dose (MTD) by Week 4. Participants who received aripiprazole/escitalopram combination therapy in the double-blind treatment period in previous studies were included in this group.
Drug: Aripiprazole · Drug: Escitalopram
Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the double-blind treatment period in previous studies were included in this group.
Drug: Aripiprazole · Drug: Escitalopram
Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received aripiprazole in the double-blind treatment period in previous studies were included in this group.
Drug: Aripiprazole · Drug: Escitalopram
Aripiprazole capsules, orally at the daily dose of 3, 6, or 12 mg, in combination with escitalopram 10 or 20 mg orally, once daily in combination with escitalopram 10 or 20 mg (i.e., the final dose taken during the previous study), orally, once daily, for 36 weeks. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 1 if the initial 6 mg/day dose was tolerated. The dose adjustments were allowed for aripiprazole to establish the MTD by Week 4. Participants who received escitalopram in the single-blind treatment period in previous studies were included in this group.
Drug: Aripiprazole · Drug: Escitalopram
Aripiprazole oral capsules
Also known as: OPC-14597
Escitalopram oral capsules
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs), Severe (Grade 3 or Higher) TEAEs, and Discontinuations From the Trial Due to TEAEs
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention. TEAE is defined as an adverse event that started after start of study drug treatment. The Common Terminology Criteria for Adverse Events v3.0 (CTCAE) was used to determine the severity wherein Grade 1=mild AE, Grade 2=moderate AE, Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death related to AE.
Time frame: From first dose up to 30 days post last dose (Up to approximately 40 weeks)
Mean Change From Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
The severity of illness was rated using a 7-point CGI-S. CGI-S scores range from 1 to 7, where 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants. A negative mean change from Baseline indicates improvement.
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Patient Global Impression - Severity of Depression Scale (PGI-S) Score
The severity of illness was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1=not depressed at all, 2=only occasionally depressed to a mild degree, 3=mildly depressed half the time, 4=moderately depressed most of the time, 5=moderately depressed almost all of the time, 6=severely depressed all the time, 7=extremely depressed all the time. A negative mean change from Baseline indicates improvement.
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities
Criteria for potentially clinically significant vital sign abnormalities: Heart rate \[beats per minute (BPM)\]: \>120, increase \>=15, \<50, decrease \>=15; systolic blood pressure \[millimeter of mercury (mmHg)\]: \>180, increase \>=20, \<90, decrease \>=20; diastolic blood pressure (mmHg): \>105, increase \>=15, \<50, decrease \>=15; orthostatic hypotension: \>=20 mmHg decrease in systolic blood pressure and \>=25 bpm increase in heart rate from supine to sitting; weight (kg) gain: increase \>=7%; or weight loss: decrease \>=7%. Only categories with at least 1 participant with event are reported.
Time frame: Up to 40 weeks
Mean Change From Baseline in Body Weight
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Body Mass Index (BMI)
BMI= weight(kg)/\[height(m)\^2\].
Time frame: Baseline, Week 26 and End of the study visit (Week 43 or before)
Number of Participants With Potentially Clinically Significant Laboratory Test Abnormalities
The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. The categories with at least one participants with abnormal lab value as assessed by the Investigator are reported.
Time frame: Up to 40 weeks
Mean Change From Baseline in Laboratory Test Results: Prolactin
Prolactin is a hormone released by the pituitary gland. The prolactin test measures the amount of prolactin in the blood. Prolactin is responsible for the breast growth and milk production during pregnancy and after birth. The normal prolactin levels range from 20 to 25 ng/mL in males and females and 80 to 400 ng/mL in pregnant women. A negative mean change from Baseline indicates reduction in the prolactin levels.
Time frame: Baseline, Weeks 8, 26, and End of the study visit (Week 43 or before)
Mean Change From Baseline in Laboratory Test Results: Hemoglobin A1c (HbA1c)
The HbA1c is also known as glycosylated hemoglobin. It is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. The mean change in the value of HbA1c was analyzed relative to Baseline. The HbA1c of \<6.0% signifies the normal blood glucose level. A negative mean change from Baseline indicates improvement.
Time frame: Baseline, Week 8, and End of the study visit (Week 43 or before)
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities
Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported. Only categories with at least 1 participant with event are reported.
Time frame: Up to 40 weeks
Number of Participants With Potentially Clinically Significant Physical Examination Findings
Time frame: Up to 40 weeks
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
The AIMS is a 12-item scale. The first 10 -items are rated from 0 to 4 (0=best, 4=worst). An item score of 0, depending on the item, either means: no abnormal involuntary movement (AIM), or no incapacitation due to AIM, or no awareness of AIM. An item score of 4 either means: severe AIM, or severe incapacitation due to AIM, or being aware of, and severe distress caused by AIM. Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, where a higher score indicates worst outcome. A negative mean change from Baseline indicates improvement.
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
The SAS is a rating scale used to measure extrapyramidal symptoms (EPS). The SAS is a 10-item scale, with each item rated from 1 to 5, with 1 being normal and 5 being the worst. The SAS total score is the sum of ratings for all 10 items, with possible total scores from 10 to 50. A negative mean change from Baseline indicates improvement.
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Clinical Assessment of Akathisia (Item 4) Score
The BARS is used to assess the presence and severity of akathisia. This scale consists of 4 items. Only item 4, the 'Global Clinical Assessment of Akathisia', was evaluated for this outcome measure. This item is rated on a 6-point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative mean change from Baseline indicates improvement.
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14, 20, 26, 32 and End of the study visit (Week 43 or before)
Percentage of Participants With Suicidal Ideation in Each Item as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
The suicidal ideation compared to Baseline was measured by an increase in suicidal ideation category (1-5 on the C-SSRS) during treatment from the maximum suicidal ideation category at Baseline, or any suicidal ideation during treatment if there is none at Baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (Question 1: wish to be dead; Question 2: non-specific active suicidal thoughts; Question 3: active suicidal ideation with any methods (not plan) without intent to act; Question 4: active suicidal ideation with some intent to act, without specific plan; Question 5: active suicidal ideation with specific plan and intent). A negative change from Baseline indicates improvement. Only those categories and timepoints which have data are reported.
Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 14 and Last Visit (Week 43 or before)
Mean Change From Baseline in Each Item as Measured by Massachusetts General Hospital Sexual Functioning Inventory (MGH SFI) Subscale Score
The MGH SFI is a measure of a participant's self-reported sexual functioning. The MGH SFI included 5 questions at the baseline assessment, each addressing experiences over the last month: Question a) interest in sex, Question b) ability to get sexually aroused, Question c) ability to achieve orgasm, Question d) ability to get and maintain an erection, and Question e) overall sexual satisfaction. The MGH SFI at post-baseline visits included one additional question: Question f) overall improvement since the last medication change. Each question/item is rated from 1 through 6. For questions a) through e), a score of 1 indicates 'greater than normal', and 6 'totally absent'. For question f), a score of 1 indicates 'very much improved', and 6 'much worse'. All question scores are analyzed separately. No total or mean score is derived. Each subscale score ranges from 0 to 6, higher scores indicates worsening. A negative mean change from Baseline indicates improvement.
Time frame: Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Overall General Subscore
The Q-LES-Q-SF is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning with the help of 14 items of total 16 items of the scale. The overall general subscore is obtained using 14 items of the scale. Each item is scored on a 5-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. The raw scores are computed to an overall general subscore of 0 to 100 where lower scores indicate less enjoyment or satisfaction with the activity. A positive change from Baseline indicates improvement.
Time frame: Baseline, Week 8, 26 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Total Score
The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The SDS Mean Score of 0 to 10 was calculated as an average of the three item scores. All three item scores needed to be available with the exception of the work/school item score when this item was not applicable. A negative mean change from Baseline indicates improvement.
Time frame: Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)
Mean Change From Baseline in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) Total Score
The CPFQ is a brief self-rated scale developed to measure cognitive and executive dysfunction in mood and anxiety disorders. It consists of 7 items. The CPFQ total score ranges from 7 to 42, with higher score representing less satisfaction in cognitive and physical functioning. A negative mean change from Baseline indicates improvement.
Time frame: Baseline, Weeks 8, 26 and End of the study visit (Week 43 or before)
Participants took part in the study at 67 investigative sites in Australia, Estonia, India, Mexico, South Korea, and the United States from 18 November 2010 to 27 September 2011.
| Milestone | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Started | 44 | 41 | 38 | 50 |
| Safety sample | 44 | 41 | 36 | 49 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 44 | 41 | 38 | 50 |
| Withdrew: Lost to follow-up | 3 | 1 | 3 | 2 |
| Withdrew: Adverse event | 5 | 7 | 5 | 3 |
| Withdrew: Sponsor discontinued study | 30 | 24 | 25 | 40 |
| Withdrew: Participant met withdrawal criteria | 1 | 1 | 0 | 1 |
| Withdrew: Investigator withdrew participant | 0 | 1 | 1 | 1 |
| Withdrew: Subject withdrew consent | 4 | 5 | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 2 | 1 | 0 |
| Withdrew: Subject met exclusion criteria | 0 | 0 | 2 | 1 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the participant and may have required medical or surgical intervention. TEAE is defined as an adverse event that started after start of study drug treatment. The Common Terminology Criteria for Adverse Events v3.0 (CTCAE) was used to determine the severity wherein Grade 1=mild AE, Grade 2=moderate AE, Grade 3=severe AE, Grade 4=life-threatening or disabling AE, Grade 5=death related to AE.
| percentage of participants | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| TEAEs | 54.5 | 70.7 | 75.0 | 67.3 |
| STEAEs | 2.3 | 9.8 | 0.0 | 0.0 |
| Severe (Grade 3 or Higher) TEAEs | 0.0 | 4.9 | 5.6 | 2.0 |
| Discontinuations from the Trial due to TEAEs | 11.4 | 17.1 | 13.9 | 6.1 |
The severity of illness was rated using a 7-point CGI-S. CGI-S scores range from 1 to 7, where 1=normal, not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely ill, 7=among the most extremely ill participants. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 3.1 ± 1.1 | 3.4 ± 1.2 | 3.4 ± 0.9 | 3.2 ± 0.7 |
| Change from Baseline at Week 1 | -0.0 ± 0.7 | -0.2 ± 0.6 | -0.2 ± 0.6 | -0.4 ± 0.9 |
| Change from Baseline at Week 2 | -0.3 ± 0.8 | -0.3 ± 0.7 | -0.4 ± 0.6 | -0.9 ± 0.9 |
| Change from Baseline at Week 4 | -0.1 ± 0.9 | -0.5 ± 0.8 | -0.6 ± 1.0 | -0.9 ± 0.9 |
| Change from Baseline at Week 6 | -0.3 ± 0.8 | -0.5 ± 0.9 | -0.5 ± 1.1 | -0.9 ± 0.6 |
| Change from Baseline at Week 8 | -0.3 ± 0.8 | -0.5 ± 0.7 | -0.7 ± 0.9 | -0.7 ± 1.0 |
| Change from Baseline at Week 14 | -0.3 ± 1.4 | -0.6 ± 0.7 | -1.0 ± 1.2 | -0.7 ± 1.0 |
| Change from Baseline at Week 20 | -0.6 ± 0.7 | -0.3 ± 1.0 | -1.2 ± 1.1 | -0.9 ± 0.7 |
| Change from Baseline at Week 26 | -0.8 ± 0.4 | 0.0 ± 0.0 | -1.0 ± 1.4 | -1.3 ± 0.8 |
| Change from Baseline at Week 32 | -1.0 ± NA | -2.0 ± NA | — | -2.0 ± 1.0 |
| Change from Baseline at End of the Study Visit (Week 43 or before) | -0.2 ± 1.1 | -0.6 ± 0.9 | -0.7 ± 1.1 | -0.9 ± 1.0 |
The severity of illness was rated using a 7-point PGI-S. PGI-S scores range from 1 to 7, where 1=not depressed at all, 2=only occasionally depressed to a mild degree, 3=mildly depressed half the time, 4=moderately depressed most of the time, 5=moderately depressed almost all of the time, 6=severely depressed all the time, 7=extremely depressed all the time. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 2.8 ± 1.2 | 3.1 ± 1.2 | 3.3 ± 1.2 | 3.2 ± 1.4 |
| Change from Baseline at Week 1 | 0.1 ± 0.8 | -0.2 ± 0.7 | -0.2 ± 0.8 | -0.6 ± 1.0 |
| Change from Baseline at Week 2 | -0.2 ± 0.9 | -0.4 ± 0.9 | -0.4 ± 0.7 | -1.0 ± 1.2 |
| Change from Baseline at Week 4 | 0.0 ± 1.1 | -0.5 ± 1.0 | -0.2 ± 1.0 | -0.9 ± 1.5 |
| Change from Baseline at Week 6 | -0.1 ± 0.9 | -0.4 ± 1.3 | -0.4 ± 0.9 | -1.1 ± 1.1 |
| Change from Baseline at Week 8 | -0.2 ± 1.0 | -0.4 ± 1.0 | -0.3 ± 0.9 | -0.9 ± 1.5 |
| Change from Baseline at Week 14 | -0.1 ± 1.8 | -0.2 ± 1.2 | -0.8 ± 1.2 | -0.9 ± 1.4 |
| Change from Baseline at Week 20 | -0.4 ± 0.9 | -0.3 ± 1.2 | -1.0 ± 1.1 | -1.3 ± 1.3 |
| Change from Baseline at Week 26 | 0.0 ± 1.4 | 0.0 ± 0.0 | -0.6 ± 2.1 | -1.0 ± 1.1 |
| Change from Baseline at Week 32 | 0.0 ± NA | -1.0 ± NA | — | 0.0 ± 1.0 |
| Change from Baseline at End of Study Visit (Week 43 or before) | -0.1 ± 1.2 | -0.3 ± 1.2 | -0.3 ± 1.2 | -0.9 ± 1.5 |
Criteria for potentially clinically significant vital sign abnormalities: Heart rate \[beats per minute (BPM)\]: \>120, increase \>=15, \<50, decrease \>=15; systolic blood pressure \[millimeter of mercury (mmHg)\]: \>180, increase \>=20, \<90, decrease \>=20; diastolic blood pressure (mmHg): \>105, increase \>=15, \<50, decrease \>=15; orthostatic hypotension: \>=20 mmHg decrease in systolic blood pressure and \>=25 bpm increase in heart rate from supine to sitting; weight (kg) gain: increase \>=7%; or weight loss: decrease \>=7%. Only categories with at least 1 participant with event are reported.
| Participants | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Orthostatic Hypotension (mmHg) | 0 | 0 | 1 | 0 |
| Weight (kg): Weight Gain >=7% | 4 | 0 | 2 | 4 |
| Weight (kg): Weight Loss >=7% | 5 | 2 | 1 | 2 |
| kg | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 93.0 ± 27.1 | 88.3 ± 23.5 | 87.0 ± 24.2 | 84.7 ± 22.6 |
| Change from Baseline at Week 1 | 0.0 ± 2.4 | 0.1 ± 1.8 | 0.1 ± 1.2 | 0.1 ± 1.3 |
| Change from Baseline at Week 2 | 0.5 ± 2.6 | 0.2 ± 2.1 | 0.2 ± 1.4 | 0.4 ± 1.5 |
| Change from Baseline at Week 4 | 0.3 ± 3.8 | 0.4 ± 2.3 | 0.4 ± 1.4 | 0.2 ± 2.1 |
| Change from Baseline at Week 6 | 0.3 ± 4.5 | 0.1 ± 2.9 | 0.3 ± 2.1 | 0.3 ± 2.8 |
| Change from Baseline at Week 8 | -0.0 ± 5.5 | -0.5 ± 3.2 | 0.4 ± 2.7 | 0.2 ± 2.7 |
| Change from Baseline at Week 14 | 2.0 ± 5.1 | -0.9 ± 4.8 | 0.7 ± 3.0 | 0.6 ± 4.3 |
| Change from Baseline at Week 20 | 3.8 ± 2.6 | 2.0 ± 1.6 | 0.4 ± 5.7 | 1.4 ± 1.4 |
| Change from Baseline at Week 26 | 5.7 ± NA | 1.4 ± NA | — | 3.3 ± 0.5 |
| Change from Baseline at Week 32 | — | -3.6 ± NA | — | — |
| Change from Baseline at Last Visit (Week 43 or before) | -0.2 ± 4.7 | 0.1 ± 3.1 | 0.1 ± 4.0 | 1.0 ± 3.7 |
BMI= weight(kg)/\[height(m)\^2\].
| kg/m^2 | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 33.4 ± 8.6 | 30.9 ± 8.1 | 31.1 ± 7.6 | 30.7 ± 7.4 |
| Change from Baseline at Week 26 | 2.3 ± NA | 0.4 ± NA | — | 1.2 ± 0.2 |
| Change from Baseline at Last Visit (Week 43 or before) | 0.0 ± 2.5 | -0.1 ± 1.1 | -0.1 ± 1.5 | 0.4 ± 1.7 |
The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance. The categories with at least one participants with abnormal lab value as assessed by the Investigator are reported.
| Participants | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Alanine Aminotransferase [Serum Glutamic Pyruvic Transaminase (SGPT)] [unit(U)/L]: >=3×ULN | 0 | 1 | 0 | 0 |
| Aspartate Aminotransferase [Serum Glutamic Oxaloacetic Transaminase (SGOT)] (U/L): >=3×ULN | 0 | 1 | 0 | 0 |
| Bilirubin, Total [mg/deciliter(dL)]: ≥2.0 | 0 | 1 | 0 | 0 |
| Cholesterol, Total, Fasting (mg/dL): ≥240 | 10 | 9 | 5 | 8 |
| Creatine phosphokinase (CPK), Total (U/L): ≥3 x ULN | 0 | 1 | 0 | 1 |
| High-density Lipoprotein (HDL) Cholesterol, Fasting (mg/dL): ≤30 | 0 | 0 | 2 | 1 |
| Low-density Lipoprotein (LDL) Cholesterol, Fasting (mg/dL): ≥160 | 6 | 5 | 4 | 8 |
| Triglycerides, Fasting (mg/dL): Men ≥160; Women ≥120 | 24 | 16 | 14 | 25 |
| Urea Nitrogen (mg/dL); >= 30 mg/dL | 0 | 0 | 1 | 0 |
| Uric Acid (mg/dL): Men ≥10.5; Women ≥8.5 | 0 | 0 | 0 | 1 |
| Eosinophils (%): ≥10 | 0 | 1 | 0 | 0 |
| Hematocrit (%): Female ≤32%; Male: ≤37% or 3 point decrease from baseline | 0 | 1 | 1 | 0 |
| Hemoglobin (g/dL): Men ≤11.5; Women ≤9.5 | 1 | 0 | 1 | 0 |
| Prolactin [nanograms (ng)/mL]: >1 ULN | 1 | 1 | 1 | 0 |
Prolactin is a hormone released by the pituitary gland. The prolactin test measures the amount of prolactin in the blood. Prolactin is responsible for the breast growth and milk production during pregnancy and after birth. The normal prolactin levels range from 20 to 25 ng/mL in males and females and 80 to 400 ng/mL in pregnant women. A negative mean change from Baseline indicates reduction in the prolactin levels.
| ng/mL | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Mean Change from Baseline at Week 8 | 0.52 ± 3.94 | 0.31 ± 4.37 | 0.62 ± 3.26 | -1.10 ± 6.88 |
| Mean Change from Baseline at Week 26 | -0.79 ± NA | -2.75 ± NA | — | -0.75 ± 0.52 |
| Mean Change from Baseline at Week Last Visit (Week 43 or before) | 0.37 ± 4.37 | 1.33 ± 4.71 | 0.30 ± 3.25 | -0.49 ± 5.57 |
The HbA1c is also known as glycosylated hemoglobin. It is the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound. The mean change in the value of HbA1c was analyzed relative to Baseline. The HbA1c of \<6.0% signifies the normal blood glucose level. A negative mean change from Baseline indicates improvement.
| percentage of HbA1c | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Mean Change from Baseline at Week 8 | — | 0.30 ± NA | — | — |
| Mean Change from Baseline at Last Visit (Week 43 or before) | -0.30 ± NA | 0.30 ± NA | — | — |
Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported. Only categories with at least 1 participant with event are reported.
| Participants | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Bradycardia: Decrease of ≥15 bpm | 1 | 0 | 0 | 0 |
| Sinus Bradycardia: Decrease of ≥15 bpm | 1 | 0 | 0 | 0 |
| Supraventricular Premature Beat: Not Present to Present | 1 | 0 | 1 | 0 |
| Ventricular Premature Beat: Not Present to Present | 0 | 1 | 1 | 0 |
| 1° Atrioventricular Block: Increase of ≥0.05 second | 0 | 1 | 0 | 0 |
| Right Bundle-branch Block: Not Present to Present | 1 | 0 | 0 | 1 |
| Myocardial Ischemia: Not Present to Present | 1 | 0 | 0 | 0 |
| Symmetrical T-wave Inversion: Not Present to Present | 3 | 1 | 0 | 0 |
| QTcB | 1 | 1 | 2 | 0 |
| QTcF | 0 | 1 | 2 | 1 |
| QTcN | 0 | 1 | 1 | 0 |
| Participants | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Physical Examination Findings | 0 | 0 | 0 | 0 |
The AIMS is a 12-item scale. The first 10 -items are rated from 0 to 4 (0=best, 4=worst). An item score of 0, depending on the item, either means: no abnormal involuntary movement (AIM), or no incapacitation due to AIM, or no awareness of AIM. An item score of 4 either means: severe AIM, or severe incapacitation due to AIM, or being aware of, and severe distress caused by AIM. Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, where a higher score indicates worst outcome. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 0.1 ± 0.5 | 0.0 ± 0.2 | 0.1 ± 0.3 | 0.1 ± 0.3 |
| Change from Baseline at Week 4 | -0.1 ± 0.5 | -0.0 ± 0.2 | 0.0 ± 0.2 | 0.2 ± 1.1 |
| Change from Baseline at Week 8 | -0.1 ± 0.6 | 0.0 ± 0.0 | 0.0 ± 0.0 | -0.1 ± 0.4 |
| Change from Baseline at Week 20 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | -0.2 ± 0.6 |
| Change from Baseline at Week 26 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Change from Baseline at Week 32 | 0.0 ± NA | 0.0 ± NA | — | 0.0 ± 0.0 |
| Change from Baseline at End of Study Visit (Week 43 or before) | -0.0 ± 0.5 | -0.0 ± 0.2 | -0.0 ± 0.4 | -0.0 ± 0.3 |
The SAS is a rating scale used to measure extrapyramidal symptoms (EPS). The SAS is a 10-item scale, with each item rated from 1 to 5, with 1 being normal and 5 being the worst. The SAS total score is the sum of ratings for all 10 items, with possible total scores from 10 to 50. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 10.1 ± 0.3 | 10.0 ± 0.2 | 10.3 ± 0.7 | 10.1 ± 0.5 |
| Change from Baseline at Week 4 | 0.0 ± 0.3 | 0.3 ± 0.7 | 0.0 ± 0.7 | 0.1 ± 0.5 |
| Change from Baseline at Week 8 | -0.1 ± 0.4 | 0.2 ± 0.5 | -0.1 ± 0.7 | -0.0 ± 1.0 |
| Change from Baseline at Week 20 | 0.0 ± 0.0 | 0.0 ± 0.0 | -0.3 ± 0.7 | -0.3 ± 0.6 |
| Change from Baseline at Week 26 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | -0.3 ± 0.8 |
| Change from Baseline at Week 32 | 0.0 ± NA | 0.0 ± NA | — | -0.7 ± 1.2 |
| Change from Baseline at End of Study Visit (Week 43 or before) | 0.1 ± 1.1 | 0.3 ± 0.8 | 0.1 ± 1.1 | -0.0 ± 0.5 |
The BARS is used to assess the presence and severity of akathisia. This scale consists of 4 items. Only item 4, the 'Global Clinical Assessment of Akathisia', was evaluated for this outcome measure. This item is rated on a 6-point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 0.2 ± 0.5 | 0.1 ± 0.4 | 0.4 ± 0.8 | 0.1 ± 0.4 |
| Change from Baseline at Week 4 | 0.1 ± 0.6 | 0.3 ± 0.7 | 0.0 ± 0.8 | 0.2 ± 0.6 |
| Change from Baseline at Week 8 | -0.1 ± 0.6 | 0.3 ± 1.0 | -0.1 ± 1.1 | -0.0 ± 0.6 |
| Change from Baseline at Week 20 | -0.1 ± 0.4 | -0.2 ± 0.4 | -0.4 ± 1.0 | -0.3 ± 0.9 |
| Change from Baseline at Week 26 | -0.2 ± 0.4 | -0.5 ± 0.7 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Change from Baseline at Week 32 | 0.0 ± NA | -1.0 ± NA | — | -0.3 ± 0.6 |
| Change from Baseline at End of Study Visit (Week 43 or before) | -0.0 ± 0.6 | 0.3 ± 0.9 | -0.1 ± 1.1 | 0.0 ± 0.5 |
The suicidal ideation compared to Baseline was measured by an increase in suicidal ideation category (1-5 on the C-SSRS) during treatment from the maximum suicidal ideation category at Baseline, or any suicidal ideation during treatment if there is none at Baseline. C-SSRS is used to assess whether participant experienced suicidal ideation (Question 1: wish to be dead; Question 2: non-specific active suicidal thoughts; Question 3: active suicidal ideation with any methods (not plan) without intent to act; Question 4: active suicidal ideation with some intent to act, without specific plan; Question 5: active suicidal ideation with specific plan and intent). A negative change from Baseline indicates improvement. Only those categories and timepoints which have data are reported.
| percentage of participants | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Question 1: Baseline | 0.0 | 12.2 | 8.3 | 4.1 |
| Question 1: Week 1 | 0.0 | 2.4 | 2.8 | 0.0 |
| Question 1: Week 2 | 0.0 | 2.4 | 2.8 | 0.0 |
| Question 1: Week 4 | 2.3 | 4.9 | 2.8 | 0.0 |
| Question 1: Week 6 | 2.3 | 4.9 | 2.8 | 0.0 |
| Question 1: Week 8 | 0.0 | 0.0 | 2.8 | 2.0 |
| Question 1: Week 14 | 2.3 | 0.0 | 0.0 | 0.0 |
| Question 1: Last Visit (Week 43 or before) | 2.3 | 2.4 | 5.6 | 0.0 |
| Question 2: Week 8 | 0.0 | 0.0 | 0.0 | 2.0 |
| Question 2: Week 14 | 2.3 | 0.0 | 0.0 | 0.0 |
| Question 2: Last Visit (Week 43 or before) | 0.0 | 0.0 | 2.8 | 0.0 |
| Question 3: Week 14 | 2.3 | 0.0 | 0.0 | 0.0 |
| Question 3: Last Visit (Week 43 or before) | 0.0 | 0.0 | 2.8 | 0.0 |
The MGH SFI is a measure of a participant's self-reported sexual functioning. The MGH SFI included 5 questions at the baseline assessment, each addressing experiences over the last month: Question a) interest in sex, Question b) ability to get sexually aroused, Question c) ability to achieve orgasm, Question d) ability to get and maintain an erection, and Question e) overall sexual satisfaction. The MGH SFI at post-baseline visits included one additional question: Question f) overall improvement since the last medication change. Each question/item is rated from 1 through 6. For questions a) through e), a score of 1 indicates 'greater than normal', and 6 'totally absent'. For question f), a score of 1 indicates 'very much improved', and 6 'much worse'. All question scores are analyzed separately. No total or mean score is derived. Each subscale score ranges from 0 to 6, higher scores indicates worsening. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Question a: Baseline | 4.2 ± 1.7 | 3.8 ± 1.5 | 4.4 ± 1.4 | 3.6 ± 1.6 |
| Question a: Change from Baseline at Week 8 | -0.1 ± 1.3 | -0.4 ± 0.9 | -0.4 ± 0.8 | -0.3 ± 1.1 |
| Question a: Change from Baseline at Week 26 | -0.2 ± 0.4 | 0.0 ± 0.0 | -0.4 ± 1.1 | 0.0 ± 0.0 |
| Question a: Change from Baseline at End of Study Visit (Week 43 or before) | -0.1 ± 1.1 | -0.3 ± 1.1 | -0.4 ± 1.2 | -0.4 ± 1.2 |
| Question b: Baseline | 3.9 ± 1.7 | 3.7 ± 1.5 | 4.1 ± 1.4 | 3.5 ± 1.6 |
| Question b: Change from Baseline at Week 8 | 0.0 ± 0.9 | -0.2 ± 0.9 | -0.1 ± 0.9 | -0.3 ± 0.9 |
| Question b: Change from Baseline at Week 26 | 0.2 ± 0.4 | 0.0 ± 0.0 | 0.0 ± 1.2 | -0.2 ± 0.4 |
| Question b: Change from Baseline at End of Study Visit (Week 43 or before) | 0.1 ± 0.8 | -0.3 ± 1.0 | -0.2 ± 1.0 | -0.3 ± 1.1 |
| Question c: Baseline | 4.0 ± 1.7 | 3.8 ± 1.5 | 4.1 ± 1.5 | 3.5 ± 1.6 |
| Question c: Change from Baseline at Week 8 | -0.1 ± 1.0 | -0.3 ± 1.1 | -0.1 ± 0.9 | -0.2 ± 0.9 |
| Question c: Change from Baseline at Week 26 | -0.2 ± 1.1 | 0.0 ± 0.0 | -0.2 ± 1.3 | -0.2 ± 0.4 |
| Question c: Change from Baseline at End of Study Visit (Week 43 or before) | -0.0 ± 1.0 | -0.4 ± 1.1 | 0.0 ± 1.1 | -0.1 ± 1.1 |
| Question d: Baseline | 2.5 ± 1.2 | 3.0 ± 1.4 | 3.6 ± 1.3 | 2.9 ± 1.3 |
| Question d: Change from Baseline at Week 8 | 0.0 ± 0.0 | 0.0 ± 0.5 | -0.4 ± 0.5 | -0.2 ± 0.4 |
| Question d: Change from Baseline at Week 26 | 0.0 ± NA | 0.5 ± 0.7 | 0.0 ± NA | 0.0 ± 0.0 |
| Question d: Change from Baseline at End of Study Visit (Week 43 or before) | 0.1 ± 0.3 | 0.0 ± 0.5 | 0.1 ± 0.9 | -0.1 ± 0.8 |
| Question e: Baseline | 4.2 ± 1.7 | 3.9 ± 1.6 | 4.4 ± 1.3 | 3.7 ± 1.6 |
| Question e: Change from Baseline at Week 8 | -0.1 ± 1.1 | -0.3 ± 0.8 | -0.3 ± 0.8 | -0.2 ± 1.1 |
| Question e: Change from Baseline at Week 26 | -0.4 ± 0.5 | 0.5 ± 0.7 | -0.4 ± 1.1 | 0.0 ± 0.6 |
| Question e: Change from Baseline at End of Study Visit (Week 43 or before) | -0.1 ± 0.9 | -0.3 ± 1.2 | -0.3 ± 1.4 | -0.3 ± 1.4 |
| Question f: Baseline | 3.3 ± 0.9 | 3.5 ± 1.2 | 3.4 ± 1.1 | 3.6 ± 1.2 |
| Question f: Change from Baseline at Week 8 | 0.1 ± 1.1 | -0.3 ± 1.1 | 0.2 ± 1.1 | -0.7 ± 1.7 |
| Question f: Change from Baseline at Week 26 | -1.0 ± 0.7 | 0.0 ± 0.0 | 0.4 ± 1.9 | -0.8 ± 1.3 |
| Question f: Change from Baseline at End of Study Visit (Week 43 or before) | -0.0 ± 1.0 | -0.2 ± 1.1 | -0.0 ± 1.6 | -0.6 ± 1.5 |
The Q-LES-Q-SF is a self-report measure designed to enable investigators to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning with the help of 14 items of total 16 items of the scale. The overall general subscore is obtained using 14 items of the scale. Each item is scored on a 5-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. The raw scores are computed to an overall general subscore of 0 to 100 where lower scores indicate less enjoyment or satisfaction with the activity. A positive change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 49.4 ± 14.7 | 50.2 ± 19.9 | 47.9 ± 16.8 | 52.2 ± 14.6 |
| Change from Baseline at Week 8 | 0.8 ± 10.4 | 3.6 ± 11.0 | 6.2 ± 9.9 | 9.5 ± 13.6 |
| Change from Baseline at Week 26 | 0.8 ± 19.6 | -0.5 ± 2.1 | 6.2 ± 22.4 | 4.3 ± 17.7 |
| Change from Baseline at End of Study visit (Week 43 or before) | 1.0 ± 14.1 | 5.0 ± 15.4 | 4.6 ± 14.3 | 10.0 ± 16.5 |
The SDS is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0= not at all, to 10= extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The SDS Mean Score of 0 to 10 was calculated as an average of the three item scores. All three item scores needed to be available with the exception of the work/school item score when this item was not applicable. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 4.6 ± 2.6 | 4.3 ± 2.7 | 5.1 ± 2.7 | 3.8 ± 2.1 |
| Change from Baseline at Week 8 | -1.1 ± 2.1 | -0.8 ± 1.6 | -2.0 ± 2.4 | -1.4 ± 1.8 |
| Change from Baseline at Week 26 | -1.9 ± 1.6 | 1.7 ± 2.4 | -2.6 ± 2.7 | -0.7 ± 4.6 |
| Change from Baseline at End of Study visit (Week 43 or before) | -0.6 ± 2.1 | -0.5 ± 2.5 | -1.6 ± 2.8 | -1.6 ± 2.2 |
The CPFQ is a brief self-rated scale developed to measure cognitive and executive dysfunction in mood and anxiety disorders. It consists of 7 items. The CPFQ total score ranges from 7 to 42, with higher score representing less satisfaction in cognitive and physical functioning. A negative mean change from Baseline indicates improvement.
| score on a scale | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Baseline | 23.0 ± 6.1 | 22.1 ± 6.5 | 24.4 ± 5.3 | 22.0 ± 6.1 |
| Change from Baseline at Week 8 | -1.3 ± 4.1 | -1.8 ± 2.6 | -2.2 ± 3.3 | -4.8 ± 7.7 |
| Change from Baseline at Week 26 | -3.8 ± 3.5 | 2.0 ± 0.0 | -2.2 ± 5.6 | -2.5 ± 6.0 |
| Change from Baseline at End of Study Visit (Week 43 or before) | -1.0 ± 4.6 | -0.2 ± 4.8 | -2.6 ± 5.0 | -3.5 ± 7.6 |
Collected over From first dose of study drug through 30 days post last dose (Up to 40 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prior Aripiprazole/Escitalopram Combination Therapy | 0/44 (0%) | 1/44 (2.3%) | 18/44 (40.9%) |
| Prior Escitalopram | 0/41 (0%) | 4/41 (9.8%) | 27/41 (65.9%) |
| Prior Aripiprazole | 0/36 (0%) | 0/36 (0%) | 33/36 (91.7%) |
| Prior Single-blind Escitalopram | 0/49 (0%) | 0/49 (0%) | 31/49 (63.3%) |
| Event | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| Gastrointestinal necrosisGastrointestinal disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| Inguinal hernia, obstructiveGastrointestinal disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| PancreatitisGastrointestinal disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| Small intestinal obstructionGastrointestinal disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| Umbilical hernia, obstructiveGastrointestinal disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| Bile duct stoneHepatobiliary disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| Cholecystitis acuteHepatobiliary disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| CholelithiasisHepatobiliary disorders | 0/44 | 1/41 | 0/36 | 0/49 |
| Pseudomembranous colitisInfections and infestations | 0/44 | 1/41 | 0/36 | 0/49 |
| Alanine aminotransferase increasedInvestigations | 0/44 | 1/41 | 0/36 | 0/49 |
| Event | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/44 | 3/41 | 7/36 | 3/49 |
| AkathisiaNervous system disorders | 2/44 | 4/41 | 3/36 | 6/49 |
| FatigueGeneral disorders | 1/44 | 0/41 | 4/36 | 4/49 |
| HeadacheNervous system disorders | 1/44 | 2/41 | 2/36 | 5/49 |
| SedationNervous system disorders | 1/44 | 2/41 | 0/36 | 5/49 |
| SomnolenceNervous system disorders | 4/44 | 2/41 | 3/36 | 2/49 |
| DiarrhoeaGastrointestinal disorders | 1/44 | 0/41 | 3/36 | 0/49 |
| Weight increasedInvestigations | 2/44 | 1/41 | 3/36 | 2/49 |
| DizzinessNervous system disorders | 3/44 | 1/41 | 3/36 | 2/49 |
| Blood glucose increasedInvestigations | 0/44 | 3/41 | 0/36 | 0/49 |
Safety Sample included all participants who received in the Treatment Phase at least one dose of aripiprazole/escitalopram combination medication as indicated on the dosing record.
| Age, Continuous(years) | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram | Total |
|---|---|---|---|---|---|
| Mean | 46.1 ± 12.0 | 45.8 ± 10.7 | 48.6 ± 10.8 | 43.4 ± 11.3 | 45.8 ± 11.3 |
| Sex: Female, Male(Participants) | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram | Total |
|---|---|---|---|---|---|
| Female | 34 | 25 | 26 | 33 | 118 |
| Male | 10 | 16 | 10 | 16 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 7 | 4 | 5 | 24 |
| Not Hispanic or Latino | 36 | 34 | 32 | 43 | 145 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Prior Aripiprazole/Escitalopram Combination Therapy | Prior Escitalopram | Prior Aripiprazole | Prior Single-blind Escitalopram | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 1 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 7 | 5 | 5 | 24 |
| White | 33 | 31 | 30 | 42 | 136 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 0 | 1 | 5 |
No study locations are listed for this record.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
No publications or documents are linked to this record.
Ran from Nov 2010 to primary completion in Sep 2011, 10 months.
Results were first posted in Dec 2021, 10 years 2 months after primary completion. A results delay was requested in Aug 2012.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aripiprazole · Escitalopram
Otsuka Pharmaceutical Development & Commercialization, Inc. →